This paper focused on CSV+ circulating tumor cells in breast cancer and used Good Future’s automated negative selection platform to enrich and evaluate them.
The study found that CSV+ CTCs, rather than EpCAM+ CTCs, were associated with higher metastatic risk.
More than 4.5 CSV+ CTCs per 2 mL of blood showed strong specificity for identifying higher-risk patients.
CSV+ CTCs also outperformed CA 15-3, CA 125, and CEA, and the combined use improved risk stratification further.
The paper reinforces the value of negative selection in preserving clinically meaningful CTC phenotypes.